INDENTURENastech Pharmaceutical Co Inc • September 30th, 2004 • Pharmaceutical preparations • New York
ARTICLE 1Escrow Agreement • September 6th, 2000 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • New York
EXHIBIT 4.2 NEITHER THIS WARRANT NOR THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") OR ANY OTHER APPLICABLE SECURITIES LAWS IN RELIANCE UPON AN EXEMPTION FROM THE...Nastech Pharmaceutical Co Inc • November 2nd, 2001 • Pharmaceutical preparations
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 5th, 2023 • Adhera Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of ______________, by and between Adhera Therapeutics, Inc., a Delaware corporation (the “Company”), and each lender party that executes the signature page hereto as a purchaser (each, a “Purchaser” and collectively, the “Purchasers”).
Exhibit 10.2 STOCK OPTION AGREEMENT (this "Agreement") dated as of January 30, 2006 (the "Grant Date"), between Nastech Pharmaceutical Company Inc., a Delaware corporation (the "Company"), and Timothy M. Duffy ("Grantee"), an employee of the Company....Stock Option Agreement • February 3rd, 2006 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • Delaware
RECITALSLease • August 2nd, 2006 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations
EMPLOYMENT AGREEMENT AGREEMENT, dated this 1st day of September, 1997 between Nastech Pharmaceutical Company Inc., a Delaware corporation (the "Company") with offices at 45 Davids Drive, Hauppauge, NY and Vincent D. Romeo, Ph.D. (the "Executive"). W I...Employment Agreement • March 31st, 1998 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • New York
BETWEENAsset Purchase Agreement • July 1st, 2003 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • California
Nastech Pharmaceutical Company Inc. 1,725,000 Shares Common Stock ($0.006 par value)Nastech Pharmaceutical Co Inc • August 30th, 2005 • Pharmaceutical preparations • New York
EXHIBIT 10.1 LOAN AGREEMENTLoan Agreement • October 15th, 2002 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • New York
EXHIBIT 10.1 SUPPLY AGREEMENTSupply Agreement • June 8th, 2006 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • New York
Exhibit 10.23 ADDENDUM TO SECURITY AGREEMENT: SECURITIES ACCOUNT THIS ADDENDUM is attached to and made a part of that certain Security Agreement: Securities Account executed by NASTECH PHARMACEUTICAL COMPANY INC. ("Debtor") in favor of WELLS FARGO...Security Agreement • March 15th, 2004 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations
1) 2 3. Incentive Compensation. The Executive shall also be entitled to annual incentive compensation of up to fifty (50)% of the applicable base salary if the Company's business objectives as set forth in the Company's annual business plan are...Employment Agreement • March 31st, 1998 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • New York
EXHIBIT 10.2 STOCK OPTION AGREEMENT (this "Agreement") dated as of October 5th, 2005 (the "Grant Date"), between Nastech Pharmaceutical Company Inc., a Delaware corporation (the "Company"), and Mr. Paul H. Johnson, Ph.D. (Grantee"), an employee of the...Stock Option Agreement • October 7th, 2005 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • Delaware
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 12th, 2021 • Adhera Therapeutics, Inc. • Pharmaceutical preparations • Florida
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 7, 2021, by and between ADHERA THERAPEUTICS INC, a Delaware corporation, with headquarters located at 8000 Innovation Parkway, Baton Rouge, LA 70820 (the “Company”) and BLUE LAKE PARTNERS, LLC, a Delaware limited liability company, with its address at 3411 Silverside Road, Tatnal Building #104, Wilmington, DE 19810 (the “Buyer”).
RECITALSPurchase Agreement • September 4th, 2003 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • New York
COMMON STOCK PURCHASE WARRANT MARINA BIOTECH, INC.Common Stock Purchase Warrant • August 10th, 2015 • Marina Biotech, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ________________________________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issuance Date and on or prior to the six (6) year anniversary of the Issuance Date (the “Termination Date”), but not thereafter, to subscribe for and purchase from Marina Biotech, Inc., a Delaware corporation (the “Company”), up to ________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 20th, 2012 • Marina Biotech, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March 19, 2012 between Marina Biotech, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
EXHIBIT 2.4 NEITHER THIS WARRANT NOR THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") OR ANY OTHER APPLICABLE SECURITIES LAWS IN RELIANCE UPON AN EXEMPTION FROM THE...Nastech Pharmaceutical Co Inc • September 6th, 2000 • Pharmaceutical preparations
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 17th, 2011 • Marina Biotech, Inc. • Pharmaceutical preparations • Illinois
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 11, 2011, by and between MARINA BIOTECH, INC., a Delaware corporation, (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
SENIOR SECURED original issue discount Convertible PROMISSORY NOTEAdhera Therapeutics, Inc. • April 23rd, 2021 • Pharmaceutical preparations • New York
THIS SENIOR SECURED ORIGINAL ISSUE DISCOUNT CONVERTIBLE PROMISSORY NOTE is a duly authorized and validly issued Senior Secured Original Issue Discount Convertible Promissory Note issued at a 10% original issue discount by Adhera Therapeutics, Inc., a Delaware corporation (the “Company”) (this “Note”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 30th, 2008 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of April 25, 2008, between Nastech Pharmaceutical Company Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
1 EXHIBIT 10.21 EMPLOYMENT AGREEMENT AGREEMENT, dated this 27th day of December, 1999 between Nastech Pharmaceutical Company Inc., a Delaware corporation ("Employer") with offices at 45 Davids Drive, Hauppauge, NY and Andrew P. Zinzi ("Employee"). W I...Employment Agreement • March 30th, 2000 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • New York
WITNESSETH:Employment Agreement • March 30th, 1999 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • New York
ARTICLE I DEFINITIONSSecurity Agreement • October 15th, 2002 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • New York
SECURITY AGREEMENTSecurity Agreement • May 5th, 2023 • Adhera Therapeutics, Inc. • Pharmaceutical preparations
This SECURITY AGREEMENT, dated as of _______________ (this “Agreement”), is among Adhera Therapeutics, Inc., a Delaware corporation (the “Company”), all of the subsidiaries of the Company (such subsidiaries, the “Guarantors” and together with the Company, the “Debtors”) and the holders of the Company’s Original Issue Discount Senior Secured Promissory Notes (collectively, the “Notes”) signatory hereto, their endorsees, transferees and assigns (collectively, the “Secured Parties”).
2 August 2001 LICENSE AGREEMENT This Agreement is made and entered into this 2 day of August, 2001 (the "Effective Date"), by and between NASTECH PHARMACEUTICAL COMPANY INC., a corporation duly organized and existing under the laws of Delaware and...License Agreement • October 29th, 2001 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • London
1 EXHIBIT 10.19 INTERNATIONAL DISTRIBUTOR AGREEMENT EFFECTIVE DATE: ____________________________ PARTIES: Nastech Pharmaceuticals Inc., 45 Davids Drive Hauppauge New York 11788 USA Fax no: 00 1 516 273 0252 ("Company") Cambridge Selfcare Diagnostics...Distributor Agreement • March 30th, 1999 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • New York
AGREEMENTAgreement • November 15th, 2002 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • Ohio
MARINA BIOTECH, INC. [______] Units Each Unit Consisting of One Share of Common Stock and One Warrant to Purchase Up To [___] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 7th, 2015 • Marina Biotech, Inc. • Pharmaceutical preparations • New York
Marina Biotech, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters listed on Schedule I hereto (the “Underwriters”), for whom Roth Capital Partners, LLC and Ladenburg Thalmann & Co. Inc. are acting as representatives (the “Representatives”) an aggregate of (i) [____] authorized but unissued shares (the “Firm Shares”) of Common Stock, par value $0.006 per share (the “Common Stock”), of the Company and (ii) Warrants (the “Firm Warrants”) to purchase up to [____] shares of Common Stock (the “Firm Warrant Shares”). The Company has granted the Underwriters the option to purchase an aggregate of up to (i) __________ additional shares of Common Stock from the Company (the “Option Shares”) and (ii) Warrants (the “Option Warrants”) to purchase up to [____] additional shares of Common Stock (the “Option Warrant Shares” and together with the Firm Warrant Shares, the “Warrant Shares”), in each case as may
COMMON STOCK PURCHASE WARRANT marina biotech, inc.Common Stock Purchase • February 5th, 2013 • Marina Biotech, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Marina Biotech, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
COMMON STOCK PURCHASE WARRANTAdhera Therapeutics, Inc. • June 29th, 2023 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, , or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the fifth year six month anniversary (December 22, 2028) of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Adhera Therapeutics, Inc., a Delaware corporation (the “Company”), up to 500,000 shares of Common Stock (subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant issued pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) entered into as of the Initial Exercise Date between the Company and the initial Holder.
Nastech Pharmaceutical Company Inc. 3,250,000 Shares Common Stock ($0.006 par value per Share) Underwriting AgreementUnderwriting Agreement • January 19th, 2007 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • New York
Each of the undersigned, Steven C. Quay, Chairman of the Board, President and Chief Executive Officer of Nastech Pharmaceutical Company Inc., a Delaware corporation (the “Company”), and Philip C. Ranker, Chief Financial Officer and Secretary of the Company, on behalf of the Company, does hereby certify pursuant to Section 6(i) of that certain Underwriting Agreement dated January 17, 2007 (the “Underwriting Agreement”) between the Company and UBS Securities LLC, that as of [date]:
Exhibit 10.25 NASTECH PHARMACEUTICAL COMPANY INC. STAND-ALONE STOCK OPTION AGREEMENT I. NOTICE OF STOCK OPTION GRANT Gregory L. Weaver [Address] You have been granted a Nonstatutory Stock Option to purchase Common Stock of the Company, subject to the...Nastech Pharmaceutical Co Inc • March 28th, 2003 • Pharmaceutical preparations • Washington
WITNESSETHLicense and Supply Agreement • August 14th, 1997 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • New York
